William A. Preston

William A. Preston

Auto-generated profile, based on publicly available information

William A. Preston

Sidney Kimmel Medical College at Thomas Jefferson University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
WPWilliam A. Preston
William A. Preston
EDEsther Drill
Esther Drill
TBThomas Boerner
Thomas Boerner
RGRebecca Gail Gelfer
Rebecca Gail Gelfer
JHJames J Harding
James J Harding
WJWilliam R. R Jarnagin
William R. R Jarnagin
PURPOSE: This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival. MATERIALS AND METHODS: Consecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival. RESULTS: In total, 224 patients diagnosed between 2004 and 2022 (n = 127 PCA; n = 97 DCA) met inclusion criteria. The median survival was 29 months (43 after resection and 17 from diagnosis for unresectable disease). Compared with PCA, DCA was enriched in TP53alt (alterations; 69% v 33%; Q < 0.01), epigenetic pathway alterations (45% v 29%; Q = 0.041), and had more total altered pathways (median 3 v 2; Q < 0.01). KRASalt frequency was similar between PCA (36%) and DCA (37%); however, DCA was enriched in KRAS G12D (19% v 9%; P = .002). No other clinicopathologic or genomic variables distinguished subtypes. In resected patients, no genomic alterations were associated with outcome. However, in unresectable patients, CDKN2Aalt (hazard ratio [HR], 2.59 [1.48 to 4.52]) and APCalt (HR, 5.11 [1.96 to 13.3]) were associated with reduced survival. For the entire cohort, irresectability (HR, 3.13 [2.25 to 4.36]), CDKN2Aalt (HR, 1.80 [1.80 to 2.68]), and APCalt (HR, 2.00 [1.04 to 3.87]) were associated with poor survival. CONCLUSION: CDKN2Aalt and APCalt were associated with poor survival in ECA, primarily in advanced disease. As PCA and DCA were genetically similar, coanalysis of PCA and DCA in future genomic studies is reasonable.

7 November 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
WPWilliam A. Preston
William A. Preston
DPDevon J. Pace
Devon J. Pace
PAPeter J. Altshuler
Peter J. Altshuler
MYMisung Yi
Misung Yi
HKHaley D. Kittle
Haley D. Kittle
ABAdam Seth Bodzin
Adam Seth Bodzin
The recent shortage of University of Wisconsin (UW) solution prompted increased utilization of histidine-tryptophan-ketoglutarate (HTK) solution for liver graft preservation. This contemporary study analyzed deceased donor liver transplant outcomes following preservation with HTK vs. UW. Patients receiving deceased donor liver transplantations between 1/1/2019 and 6/30/2022 were retrospectively identified utilizing the Organ Procurement and Transplant Network database, stratified by preservation with HTK vs. UW, and a propensity score matching analysis was performed. Outcomes assessed included rates of primary nonfunction, graft survival, and patient survival. There were 4,447 patients in each cohort. Primary nonfunction occurred in 60 (1.35%) patients in the HTK group vs. 25 (0.54%) in the UW group (p<0.001). HTK was associated with lower 90-day graft survival (94.39% vs. 96.09%, p<0.001) and 90-day patient survival (95.97% vs. 97.38%, p=0.001). Unmatched donation after cardiac death-specific analysis of HTK vs. UW demonstrated respective rates of primary nonfunction of 1.63% vs. 0.82% (p=0.20), 90-day graft survival of 92.50% vs. 95.29% (p=0.069), and 90-day patient survival of 93.90% vs. 96.35% (p=0.077). These results suggest that HTK may not be an equivalent preservation solution for deceased donor liver transplantation.

12 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
WPWilliam A. Preston
William A. Preston
NSNina R. Spitofsky
Nina R. Spitofsky
ABAdam Seth Bodzin
Adam Seth Bodzin
Background: Robotic hepatectomy represents an appealing treatment modality for resectable hepatocellular carcinoma (HCC). A contemporary review of robotic hepatectomy compared to laparoscopic/open hepatectomy is necessary. Methods: We performed a literature review to identify studies between 2018–2024 comparing robotic to laparoscopic/open hepatectomy for HCC with measurable outcomes. Results: A total of 10 studies were identified, including 943 patients undergoing robotic hepatectomy compared to 1678 patients undergoing laparoscopic/open hepatectomy. Generally, while similar short/long-term survival was noted across all resection modalities, robotic hepatectomy was associated with longer operative time, shorter length of stay, and less post-operative complications. An additional 4 studies were evaluated in the context of HCC, reviewing the prognostic value of robotic hepatectomy margins, robotic hepatectomy in the context of metabolic syndrome, “huge” (>10 cm) HCCs, and robotic hepatectomy vs. microwave ablation. Conclusions: Robotic hepatectomy is a safe alternative to laparoscopic/open hepatectomy for HCC that provides similar oncological/long-term outcomes, while potentially decreasing post-operative complications and length of stay.

10 October 2023 in Transplantation Direct
Verified
Journal Article
Open access
PAPeter J. Altshuler
Peter J. Altshuler
DPDevon J. Pace
Devon J. Pace
WPWilliam A. Preston
William A. Preston
SVSage A. Vincent
Sage A. Vincent
ASAshesh P. Shah
Ashesh P. Shah
ABAdam Seth Bodzin
Adam Seth Bodzin
Background. Organ donors supported by extracorporeal membrane oxygenation (ECMO) have historically been considered high-risk and are judiciously utilized. This study examines transplant outcomes using renal allografts from donors supported on ECMO for nondonation purposes. Methods. Retrospective review of the Gift of Life (Pennsylvania, New Jersey, Delaware) organ procurement organization database, cross-referenced to the Organ Procurement and Transplantation Network database, assessed kidney transplants using donors supported on venoarterial (VA) and venovenous (VV) ECMO for nondonation purposes. Transplants using VA- and VV-ECMO donors were compared with Kidney Donor Profile Index (KDPI)-stratified non-ECMO donors. Regression modeling of the entire ECMO and non-ECMO populations assessed ECMO as predictive of graft survival. Additional regression of the ECMO population alone assessed for donor features associated with graft survival. Results. Seventy-eight ECMO donors yielded 128 kidney transplants (VA: 80, VV: 48). Comparing outcomes using these donors to kidney transplants using organs from KDPI-stratified non-ECMO donors, VA- and VV-ECMO donor grafts conferred similar rates of delayed graft function and posttransplant renal function to KDPI-matched non-ECMO counterparts. VA-ECMO kidneys demonstrated superior graft survival compared with the lowest-quality (KDPI 86%–100%) non-ECMO kidneys and similar graft survival to KDPI <85% non-ECMO kidneys. VV-ECMO showed inferior graft survival to all but the lowest-quality (KDPI 86%–100%) non-ECMO kidneys. VV-ECMO, but not VA-ECMO, was associated with increased risk of graft loss on multivariable regression (hazard ratios—VA: 1.02, VV: 2.18). Higher KDPI, advanced age, increased body mass index, hypertension, and diabetes were identified as high-risk features of ECMO donors. Conclusions. Kidney transplantation using appropriately selected ECMO donors can safely expand the donor pool. Ongoing studies are necessary to determine best practice patterns using kidneys from these donors. Export

15 July 2026
Verified
Book Chapter
Closed access
PDF file
WPWilliam A. Preston
William A. Preston
ABAdam Seth Bodzin
Adam Seth Bodzin